Target hemoglobin in patients with renal failure

Nephron

Volumn 89, Issue 2, 2001, Pages 135-144

  Eckardt, K U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anemia; Dialysis; Erythropoietin; Left ventricular hypertrophy; Mortality; Predialysis; Quality of life

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CASE REPORT; COST BENEFIT ANALYSIS; DIALYSIS; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; MALE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

AGED; ANEMIA; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE; MALE; MIDDLE AGED;

EID: 0034830539     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046060     Document Type: Article

References (60)

1. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin
2. Erythropoietin: Oxygen-dependent control of erythropoiesis and its failure in renal disease
3. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
4. European best practice guidelines for the management of anaemia in patients with chronic renal failure
5. European survey of anaemia mangement (ESAM): Target hemoglobin
6. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin
7. Acute and chronic cardiovascular adjustments to induced anemia in dogs
8. The oxygen affinity of hemoglobin in chronic renal failure
9. 2 homeostasis by hypoxia-inducible factor 1
10. Examination of the blood
11. Different hematologic responses to hypoxia in Sherpas and Quechua Indians
12. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis
13. The definition of anemia in older persons
14. Erythropoietin in polycystic kidneys
15. Cardiovascular mortality of patients with polycystic kidney disease: Is there a lesson to learn?
16. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
17. Hematocrit level and associated mortality in hemodialysis patients
18. Cardiovascular consequences of renal anaemia and erythropoietin therapy
19. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
20. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
21. Outcome and risk factors for left ventricular disorders in chronic uremia
22. Left ventricular hypertrophy - Pathogenesis, detection and prognosis
23. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy
24. Impact of left-ventricular hypertrophy on end-stage renal disease
25. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin
26. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin
27. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients
28. Effects of oxygen breathing and erythropoietin on hypoxic vasodilatation in uremic anemia
29. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy
30. In vivo and in vitro pressor effects of erythropoietin in rats
31. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels
32. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells
33. Pathogenesis and treatment of the anemia of chronic disease
34. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients
35. The iron hypothesis: Does iron play a role in atherosclerosis?
36. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women
37. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation
38. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
39. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients
40. Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure
41. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
42. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients
43. Normalizing hematocrit in dialysis patients improves brain function
44. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study)
45. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities
46. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients
47. After 15 years of success - Perspectives of EPO therapy
48. Anemia of the regular hemodialysis patient and its treatment
49. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass
50. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia
51. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialyis patients
52. Myocyte/capillary mismatch in the heart of uremic patients
53. Capillary/myocyte mismatch in the heart in renal failure: A role for erythropoietin?
54. Diffuse intermyocardiocytic fibrosis in uraemic patients
55. The use od subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
56. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?
57. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
58. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system
59. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector